Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Guggenheim Downgrades Prometheus Biosciences to Neutral, Lowers Price Target to $200

Author: Benzinga Newsdesk | April 17, 2023 08:29am

Guggenheim analyst Yatin Suneja downgrades Prometheus Biosciences (NASDAQ:RXDX) from Buy to Neutral and lowers the price target from $225 to $200.

Posted In: RXDX